The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
The company uses iPS cells to develop treatments for diseases relating to the kidney
Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024
Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Subscribe To Our Newsletter & Stay Updated
